{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:05:53Z","timestamp":1789981553110,"version":"4.0.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discover Nano"],"DOI":"10.1186\/s11671-026-04927-6","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:48:05Z","timestamp":1789980485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanoparticle based drug delivery systems improve antimalarial efficacy and vaccine performance in African research and clinical settings"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-3782","authenticated-orcid":false,"given":"Reuben Samson","family":"Dangana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel Ehizuelen","family":"Ebhohimen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibemusu Micheal","family":"Otele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onosolesena Dennis","family":"Idiakheua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8337-6294","authenticated-orcid":false,"given":"Moses","family":"Okpeku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"4927_CR1","unstructured":"Organization, WH World Malaria Report 2022; World Health Organization, 2022; ISBN 9240064893."},{"key":"4927_CR2","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2666-5247(24)00016-8","volume":"5","author":"P Venkatesan","year":"2024","unstructured":"Venkatesan P. The 2023 WHO World Malaria Report. Lancet Microbe. 2024;5:e214.","journal-title":"Lancet Microbe"},{"key":"4927_CR3","unstructured":"Organization, WH Global Malaria Programme Operational Strategy 2024-2030; World Health Organization, 2024; ISBN 9240090142."},{"key":"4927_CR4","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/S1473-3099(21)00142-0","volume":"21","author":"A Uwimana","year":"2021","unstructured":"Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium Falciparum Kelch13 R561H Genotypes with Delayed Parasite Clearance in Rwanda: An Open-Label, Single-Arm, Multicentre, Therapeutic Efficacy Study. Lancet Infect Dis. 2021;21:1120\u20138.","journal-title":"Lancet Infect Dis"},{"key":"4927_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, et al. Evidence of Artemisinin-Resistant Malaria in Africa. New England Journal of Medicine. 2021;385:1163\u201371.","journal-title":"New England Journal of Medicine"},{"key":"4927_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of Artemisinin Resistance in Plasmodium Falciparum Malaria. New England Journal of Medicine. 2014;371:411\u201323.","journal-title":"New England Journal of Medicine"},{"key":"4927_CR7","doi-asserted-by":"publisher","first-page":"2200518","DOI":"10.1002\/mabi.202200518","volume":"23","author":"WMR Matshe","year":"2023","unstructured":"Matshe WMR, Tshweu LL, Mvango S, Cele ZED, Chetty AS, Pilcher LA, et al. A Water\u2010Soluble Polymer\u2010Lumefantrine Conjugate for the Intravenous Treatment of Severe Malaria. Macromol Biosci. 2023;23:2200518.","journal-title":"Macromol Biosci"},{"key":"4927_CR8","doi-asserted-by":"publisher","first-page":"e00244","DOI":"10.1016\/j.parepi.2022.e00244","volume":"17","author":"L Gujjari","year":"2022","unstructured":"Gujjari L, Kalani H, Pindiprolu SK, Arakareddy BP, Yadagiri G. Current Challenges and Nanotechnology-Based Pharmaceutical Strategies for the Treatment and Control of Malaria. Parasite Epidemiol. Control. 2022;17:e00244.","journal-title":"Parasite Epidemiol. Control"},{"key":"4927_CR9","doi-asserted-by":"publisher","first-page":"37383","DOI":"10.1021\/acsami.5c07366","volume":"17","author":"F Khalid-Salako","year":"2025","unstructured":"Khalid-Salako F, Salimi Khaligh S, Fathi F, Demirci OC, \u00d6ncer N, Kurt H, et al. The Nanocarrier Landscape\u2500 Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective. ACS Appl. Mater. Interfaces. 2025;17:37383\u2013403.","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"4927_CR10","doi-asserted-by":"publisher","first-page":"125163","DOI":"10.1016\/j.ijpharm.2024.125163","volume":"670","author":"A Mishra","year":"2025","unstructured":"Mishra A, Qamar F, Ashrafi K, Fatima S, Samim M, Mohmmed A, et al. Emerging Nanotechnology-Driven Drug Delivery Solutions for Malaria: Addressing Drug Resistance and Improving Therapeutic Success. Int J Pharm. 2025;670:125163.","journal-title":"Int J Pharm"},{"key":"4927_CR11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/pharmaceutics17091216","volume":"17","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Xiu R, Wang C, Wang J, Guo D, Luo W, et al. Nanoformulation-Based Transdermal Drug Delivery: A Paradigm Shift in Antiparasitic Therapy for Zoonotic Diseases. Pharmaceutics. 2025;17:1216.","journal-title":"Pharmaceutics"},{"key":"4927_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/978-981-99-2302-1_20","volume-title":"Recent Advances in Pharmaceutical Innovation and Research","author":"G Yadagiri","year":"2023","unstructured":"Yadagiri G, Mudavath SL. Current Challenges and Nanotechnology-Based Pharmaceutical Approaches for the Treatment and Control of Visceral Leishmaniasis. Recent Advances in Pharmaceutical Innovation and Research. Springer; 2023. p. 479\u201398."},{"key":"4927_CR13","doi-asserted-by":"publisher","first-page":"124746","DOI":"10.1016\/j.ijpharm.2024.124746","volume":"666","author":"S Kele\u015f","year":"2024","unstructured":"Kele\u015f S, Alakbarli J, Akg\u00fcl B, Baghirova M, Imamova N, Barati A, et al. Nanotechnology Based Drug Delivery Systems for Malaria. Int J Pharm. 2024;666:124746.","journal-title":"Int J Pharm"},{"key":"4927_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","volume":"397","author":"MS Datoo","year":"2021","unstructured":"Datoo MS, Natama MH, Som\u00e9 A, Traor\u00e9 O, Rouamba T, Bellamy D, et al. Efficacy of a Low-Dose Candidate Malaria Vaccine, R21 in Adjuvant Matrix-M, with Seasonal Administration to Children in Burkina Faso: A Randomised Controlled Trial. The Lancet. 2021;397:1809\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(21)00943-0","journal-title":"The Lancet"},{"key":"4927_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo MS, Dicko A, Tinto H, Ou\u00e9draogo JB, Hamaluba M, Olotu A, et al. Safety and Efficacy of Malaria Vaccine Candidate R21\/Matrix-M in African Children: A Multicentre, Double-Blind, Randomised, Phase 3 Trial. The Lancet. 2024;403:533\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)02511-4","journal-title":"The Lancet"},{"key":"4927_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12668-025-02214-9","volume":"15","author":"A Khan","year":"2025","unstructured":"Khan A, Ashiq B, Qadri TA, Khattak WA, Anas M, Khan RA, et al. Nanotechnology Solutions For Advancing Sustainable Development Goals (SDGs): Integrating Nanomaterials For Global Sustainability. Bionanoscience. 2025;15:1\u201322.","journal-title":"Bionanoscience"},{"key":"4927_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4018\/979-8-3693-9153-2.ch010","volume-title":"Public Private Partnership Dynamics for Economic Development","author":"M Dzingirai","year":"2025","unstructured":"Dzingirai M. Harnessing New Technologies Public-Private Partnerships for Sustainable Development. Public Private Partnership Dynamics for Economic Development. IGI Global Scientific Publishing; 2025. p. 199\u2013212."},{"key":"4927_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3390\/su17031250","volume":"17","author":"UT Khatoon","year":"2025","unstructured":"Khatoon UT, Velidandi A. An Overview on the Role of Government Initiatives in Nanotechnology Innovation for Sustainable Economic Development and Research Progress. Sustainability. 2025;17:1250.","journal-title":"Sustainability"},{"key":"4927_CR19","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 Explanation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews. BMJ. 2021;372:n160.","journal-title":"BMJ"},{"key":"4927_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s11671-025-04215-9","volume":"20","author":"RS Dangana","year":"2025","unstructured":"Dangana RS, Okon M, Ben, Orire IE, Sanusi IO, Terkimbi SD, et al. Systematic Review of Peptide Nanoparticles for Improved Diabetes Outcomes: Insights and Opportunities. Discover Nano. 2025;20:41.","journal-title":"Discover Nano"},{"key":"4927_CR21","doi-asserted-by":"publisher","unstructured":"Dangana, RS; Sanusi, IO; Okon, M Ben; Terkimbi, SD; Ayim, G; et al. Comprehensive Evaluation of Biochar Influence on Soil Microbial Diversity, Nutrient Cycling and Contaminant Remediation Using Systematic Review and Meta-Analysis. 2025. https:\/\/doi.org\/10.1007\/s43621-025-02238-x","DOI":"10.1007\/s43621-025-02238-x"},{"key":"4927_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE\u2019s Risk of Bias Tool for Animal Studies. BMC Med Res Methodol. 2014;14:43.","journal-title":"BMC Med Res Methodol"},{"key":"4927_CR23","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"4927_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk\u2010of\u2010bias VISualization (Robvis): An R Package and Shiny Web App for Visualizing Risk\u2010of\u2010bias Assessments. Res. Synth. Methods. 2021;12:55\u201361.","journal-title":"Res. Synth. Methods"},{"key":"4927_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13065-025-01422-4","volume":"19","author":"FC Kenechukwu","year":"2025","unstructured":"Kenechukwu FC, Ugwu KC, Offorbuike CS, Ojukwu EM, Gugu TH, Eze RE, et al. Solidified Reverse Micellar Solution-Based Chitosan-Coated Solid Lipid Nanoparticles as a New Approach to Enhance Oral Delivery of Artemether in Malaria Treatment. BMC Chem. 2025;19:64 https:\/\/doi.org\/10.1186\/s13065-025-01422-4","journal-title":"BMC Chem"},{"key":"4927_CR26","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.4314\/ahs.v20i4.20","volume":"20","author":"PA Akpa","year":"2020","unstructured":"Akpa PA, Ugwuoke JA, Attama AA, Ugwu CN, Ezeibe EN, Momoh MA, et al. Improved Antimalarial Activity of Caprol-Based Nanostructured Lipid Carriers Encapsulating Artemether-Lumefantrine for Oral Administration. Afr Health Sci. 2020;20:1679\u201397.","journal-title":"Afr Health Sci"},{"key":"4927_CR27","doi-asserted-by":"publisher","first-page":"6365","DOI":"10.2147\/IJN.S92755","volume":"11","author":"PO Nnamani","year":"2016","unstructured":"Nnamani PO, Ugwu AA, Ibezim EC, Kenechukwu FC, Akpa PA, Ogbonna JDN, et al. Sustained-Release Liquisolid Compact Tablets Containing Artemether-Lumefantrine as Alternate-Day Regimen for Malaria Treatment to Improve Patient Compliance. Int J Nanomedicine. 2016;11:6365\u201378. https:\/\/doi.org\/10.2147\/IJN.S92755","journal-title":"Int J Nanomedicine"},{"key":"4927_CR28","doi-asserted-by":"publisher","first-page":"e26868","DOI":"10.1016\/j.heliyon.2024.e26868","volume":"10","author":"PA Odera","year":"2024","unstructured":"Odera PA, Otieno G, Onyango JO, Owuor JJ, Oloo FA, Ongas M, et al. NANOPARTICLE-BASED Formulation of Dihydroartemisinin-Lumefantrine Duo-Drugs: Preclinical Evaluation and Enhanced Antimalarial Efficacy in a Mouse Model. Heliyon. 2024;10:e26868 https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26868","journal-title":"Heliyon"},{"key":"4927_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s11671-024-04121-6","volume":"19","author":"BPT de Moraes","year":"2024","unstructured":"de Moraes BPT, da Silva KP, Paese K, Sinhorin AP, Guterres SS, Pohlmann AR, et al. Effects of Nanocapsules Containing Lumefantrine and Artemether in an Experimental Model of Cerebral Malaria. Discover Nano. 2024;19:184.","journal-title":"Discover Nano"},{"key":"4927_CR30","doi-asserted-by":"publisher","first-page":"16934","DOI":"10.3390\/ijms242316934","volume":"24","author":"A Bashi","year":"2023","unstructured":"Bashi A, Lekpor C, Hood JL, Thompson WE, Stiles JK, Driss A. Modulation of Heme-Induced Inflammation Using MicroRNA-Loaded Liposomes: Implications for Hemolytic Disorders Such as Malaria and Sickle Cell Disease. Int J Mol Sci. 2023;24:16934 https:\/\/doi.org\/10.3390\/ijms242316934","journal-title":"Int J Mol Sci"},{"key":"4927_CR31","doi-asserted-by":"publisher","first-page":"42014","DOI":"10.1021\/acsomega.3c04587","volume":"8","author":"R Tiwari","year":"2023","unstructured":"Tiwari R, Gupta RP, Singh VK, Kumar A, Rajneesh, Madhukar P, et al. Nanotechnology-Based Strategies in Parasitic Disease Management: From Prevention to Diagnosis and Treatment. ACS Omega. 2023;8:42014\u201327.","journal-title":"ACS Omega"},{"key":"4927_CR32","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.coi.2012.03.008","volume":"24","author":"CR Alving","year":"2012","unstructured":"Alving CR, Peachman KK, Rao M, Reed SG. Adjuvants for Human Vaccines. Curr Opin Immunol. 2012;24:310\u20135.","journal-title":"Curr Opin Immunol"},{"key":"4927_CR33","doi-asserted-by":"publisher","unstructured":"Okoth, WA; Ho, M; Zaman, M; Cooper, E; Som, P; Burgess, M; et al. Transcending Protective Immunity in Rodent Models. 2023, 14. https:\/\/doi.org\/10.1128\/mbio.02547-23","DOI":"10.1128\/mbio.02547-23"},{"key":"4927_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-023-00786-9","volume":"8","author":"N Kunkeaw","year":"2023","unstructured":"Kunkeaw N, Nguitragool W, Takashima E, Kangwanrangsan N, Muramatsu H, Tachibana M, et al. A Pvs25 MRNA Vaccine Induces Complete and Durable Transmission-Blocking Immunity to Plasmodium Vivax. NPJ Vaccines. 2023;8:1\u201310. https:\/\/doi.org\/10.1038\/s41541-023-00786-9","journal-title":"NPJ Vaccines"},{"key":"4927_CR35","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1021\/acs.molpharmaceut.5c01296","volume":"22","author":"S Das","year":"2025","unstructured":"Das S, Chatterjee A, Manna J, Das Mandal SK, Maiti TK, Bhattacharyya TK. Systems-Integrated Thermostable Vaccine Delivery: Converging Cold-Chain-Free Design, AI-Augmented Formulation, and Climate-Resilient Infrastructure. Mol Pharm. 2025;22:7285\u2013312.","journal-title":"Mol Pharm"},{"key":"4927_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. MRNA Vaccines\u2014a New Era in Vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"4927_CR37","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1631\/jzus.B1600389","volume":"18","author":"K Dauda","year":"2017","unstructured":"Dauda K, Busari Z, Morenikeji O, Afolayan F. Poly (D, L -Lactic- Co -Glycolic Acid) -Based Artesunate Nanoparticles: Formulation, Antimalarial and Toxicity Assessments. J Zhejiang Univ Sci B. 2017;18:977\u201385.","journal-title":"J Zhejiang Univ Sci B"},{"key":"4927_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2018.00562","volume":"9","author":"O Oyeyemi","year":"2018","unstructured":"Oyeyemi O, Morenkeji O, Afolayan F, Dauda K, Busari Z, Meena J, et al. Curcumin-Artesunate Based Polymeric Nanoparticle; Antiplasmodial and Toxicological Evaluation in Murine Model. Front Pharmacol. 2018;9:1\u20138. https:\/\/doi.org\/10.3389\/fphar.2018.00562","journal-title":"Front Pharmacol"},{"key":"4927_CR39","doi-asserted-by":"publisher","unstructured":"Islam, MS; Tadele, DT; Mekonnen, TH Corn Zein Nanocarriers for Agrochemical Delivery and Smart Packaging. Adv. Sustain. Syst. 2025, e00922. https:\/\/doi.org\/10.1002\/adsu.202500922","DOI":"10.1002\/adsu.202500922"},{"key":"4927_CR40","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/pharmaceutics17070944","volume":"17","author":"Y Liu","year":"2025","unstructured":"Liu Y, An D, Meng X, Deng S, Liu G. Zein-Based Nanocarriers: Advances in Oral Drug Delivery. Pharmaceutics. 2025;17:944.","journal-title":"Pharmaceutics"},{"key":"4927_CR41","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/09205063.2024.2438493","volume":"36","author":"S Sudhakar Gomte","year":"2025","unstructured":"Sudhakar Gomte S, Sanjay Shewale R, Kedarnath Vidhate M, Girish Agnihotri T, Peddinti V, Rout B, et al. Zein-Based Nanoparticulate Systems: A Journey through Fabrication. Targeting Strategies and Biomedical Applications. J. Biomater. Sci. Polym. Ed. 2025;36:1124\u201371.","journal-title":"Targeting Strategies and Biomedical Applications. J. Biomater. Sci. Polym. Ed."},{"key":"4927_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-21351-8","volume":"8","author":"SA Amolegbe","year":"2018","unstructured":"Amolegbe SA, Hirano Y, Adebayo JO, Ademowo OG, Balogun EA, Obaleye JA, et al. Mesoporous Silica Nanocarriers Encapsulated Antimalarials with High Therapeutic Performance. Sci Rep. 2018;8:1\u20139. https:\/\/doi.org\/10.1038\/s41598-018-21351-8","journal-title":"Sci Rep"},{"key":"4927_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics16030357","volume":"16","author":"R de Andrade","year":"2024","unstructured":"de Andrade R, Schmidt R, de C, dos R, Gomes LS, Colina-Vegas L, et al. Magnetic Mesoporous Silica for Targeted Drug Delivery of Chloroquine: Synthesis, Characterization, and In Vitro Evaluation. Pharmaceutics. 2024;16:1\u201314. https:\/\/doi.org\/10.3390\/pharmaceutics16030357","journal-title":"Pharmaceutics"},{"key":"4927_CR44","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1080\/21691401.2018.1491481","volume":"46","author":"NL Dlamini","year":"2018","unstructured":"Dlamini NL, Mukaya HE, Van Zyl RL, Jansen van Vuuren NC, Mbianda XY. Carbon Nanospheres Conjugated Bisphosphonates: Synthesis, Characterization and in Vitro Antimalarial Activity. Artif. Cells Nanomed. Biotechnol. 2018;46:S287\u2013S296. https:\/\/doi.org\/10.1080\/21691401.2018.1491481","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"4927_CR45","doi-asserted-by":"publisher","first-page":"16671","DOI":"10.1007\/s11356-016-6832-9","volume":"23","author":"K Murugan","year":"2016","unstructured":"Murugan K, Panneerselvam C, Subramaniam J, Madhiyazhagan P, Hwang J-S, Wang L, et al. Eco-Friendly Drugs from the Marine Environment: Spongeweed-Synthesized Silver Nanoparticles Are Highly Effective on Plasmodium Falciparum and Its Vector Anopheles Stephensi, with Little Non-Target Effects on Predatory Copepods. Environmental Science and Pollution Research. 2016;23:16671\u201385.","journal-title":"Environmental Science and Pollution Research"},{"key":"4927_CR46","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s11671-024-04098-2","volume":"19","author":"S Tiwari","year":"2024","unstructured":"Tiwari S, Kumar R, Devi S, Sharma P, Chaudhary NR, Negi S, et al. Biogenically Synthesized Green Silver Nanoparticles Exhibit Antimalarial Activity. Discover nano. 2024;19:136.","journal-title":"Discover nano"},{"key":"4927_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s11671-025-04311-w","volume":"20","author":"TF Egza","year":"2025","unstructured":"Egza TF, Kebede EM, Perumal RD. Advancing Malaria Treatment with Magnetic and Mesoporous Silica Nanoparticles Loaded with Sulfadoxine-Pyrimethamine: A Review. Discover Nano. 2025;20:199.","journal-title":"Discover Nano"},{"key":"4927_CR48","doi-asserted-by":"publisher","first-page":"159517","DOI":"10.1016\/j.scitotenv.2022.159517","volume":"857","author":"C Kamaraj","year":"2023","unstructured":"Kamaraj C, Ragavendran C, Kumar RCS, Sabarathinam S, Vetrivel C, Vaithiyalingam M, et al. RETRACTED: Synthesize Palladium Nanoparticles from the Macroalgae Sargassum Fusiforme: An Eco-Friendly Tool in the Fight against Plasmodium Falciparum? Sci Total Environ. 2023;857:159517.","journal-title":"Sci Total Environ"},{"key":"4927_CR49","doi-asserted-by":"publisher","first-page":"1076320","DOI":"10.3389\/fbioe.2022.1076320","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Sebastian S, Huang J, Corbascio T, Engellau J, Lidgren L, et al. Longitudinal in Vivo Biodistribution of Nano and Micro Sized Hydroxyapatite Particles Implanted in a Bone Defect. Front Bioeng Biotechnol. 2022;10:1076320.","journal-title":"Front Bioeng Biotechnol"},{"key":"4927_CR50","doi-asserted-by":"publisher","first-page":"e29773","DOI":"10.1016\/j.heliyon.2024.e29773","volume":"10","author":"T Kamalesh","year":"2024","unstructured":"Kamalesh T. Advances in Stabilization of Metallic Nanoparticle with Biosurfactants-a Review on Current Trends. Heliyon. 2024;10:e29773.","journal-title":"Heliyon"},{"key":"4927_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-017-0295-0","volume":"15","author":"CP Karch","year":"2017","unstructured":"Karch CP, Doll TAPF, Paulillo SM, Nebie I, Lanar DE, Corradin G, et al. The Use of a P. Falciparum Specific Coiled-Coil Domain to Construct a Self-Assembling Protein Nanoparticle Vaccine to Prevent Malaria. J Nanobiotechnology. 2017;15:1\u201310. https:\/\/doi.org\/10.1186\/s12951-017-0295-0","journal-title":"J Nanobiotechnology"},{"key":"4927_CR52","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","volume":"10","author":"MF Bachmann","year":"2010","unstructured":"Bachmann MF, Jennings GT. Vaccine Delivery: A Matter of Size, Geometry, Kinetics and Molecular Patterns. Nat Rev Immunol. 2010;10:787\u201396.","journal-title":"Nat Rev Immunol"},{"key":"4927_CR53","volume-title":"WHO Recommends R21\/Matrix-M Vaccine for Malaria Prevention in Updated Advice on Immunization","author":"WH Organization","year":"2023","unstructured":"Organization WH. WHO Recommends R21\/Matrix-M Vaccine for Malaria Prevention in Updated Advice on Immunization. Geneva: World Health Organization; 2023."},{"key":"4927_CR54","doi-asserted-by":"publisher","first-page":"e31472","DOI":"10.1371\/journal.pone.0031472","volume":"7","author":"JJ Moon","year":"2012","unstructured":"Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. Antigen-Displaying Lipid-Enveloped PLGA Nanoparticles as Delivery Agents for a Plasmodium Vivax Malaria Vaccine. PLoS ONE. 2012;7:e31472 https:\/\/doi.org\/10.1371\/journal.pone.0031472","journal-title":"PLoS ONE"},{"key":"4927_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22031141","volume":"22","author":"Y Boateng-Marfo","year":"2021","unstructured":"Boateng-Marfo Y, Dong Y, Ng WK, Lin HS. Artemether-Loaded Zein Nanoparticles: An Innovative Intravenous Dosage Form for the Management of Severe Malaria. Int J Mol Sci. 2021;22:1\u201322. https:\/\/doi.org\/10.3390\/ijms22031141","journal-title":"Int J Mol Sci"},{"key":"4927_CR56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng.3189","volume":"47","author":"O Miotto","year":"2015","unstructured":"Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic Architecture of Artemisinin-Resistant Plasmodium Falciparum. Nat Genet. 2015;47:226\u201334.","journal-title":"Nat Genet"},{"key":"4927_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S2666-5247(24)00084-3","volume":"6","author":"N Venkatraman","year":"2025","unstructured":"Venkatraman N, Tiono AB, Bowyer G, Bellamy DG, Stockdale LK, Powlson J, et al. Evaluation of a Novel Malaria Anti-Sporozoite Vaccine Candidate, R21 in Matrix-M Adjuvant, in the UK and Burkina Faso: Two Phase 1, First-in-Human Trials. Lancet Microbe. 2025;6:1\u201311. https:\/\/doi.org\/10.1016\/S2666-5247(24)00084-3","journal-title":"Lancet Microbe"},{"key":"4927_CR58","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11051-020-05058-4","volume":"22","author":"M Akbari","year":"2020","unstructured":"Akbari M, Morad R, Maaza M. First Principle Study of Silver Nanoparticle Interactions with Antimalarial Drugs Extracted from Artemisia Annua Plant. J Nanoparticle Res. 2020;22:331 https:\/\/doi.org\/10.1007\/s11051-020-05058-4","journal-title":"J Nanoparticle Res"},{"key":"4927_CR59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1021\/acsinfecdis.2c00336","volume":"9","author":"NM Hamelmann","year":"2022","unstructured":"Hamelmann NM, Paats J-WD, Avalos-Padilla Y, Lantero E, Spanos L, Siden-Kiamos I, et al. Single-Chain Polymer Nanoparticles Targeting the Ookinete Stage of Malaria Parasites. ACS Infect. Dis. 2022;9:56\u201364.","journal-title":"ACS Infect. Dis."},{"key":"4927_CR60","unstructured":"Organization, WH WHO Malaria Policy Advisory Group (MPAG) Meeting Report, 4, 5 and 7 March 2024; World Health Organization, 2024; ISBN 9240095292."},{"key":"4927_CR61","doi-asserted-by":"publisher","first-page":"e1338","DOI":"10.1016\/S2214-109X(25)00201-3","volume":"13","author":"L Pandya","year":"2025","unstructured":"Pandya L, Norstedt I, Seychell M, Cooke E, de la Mata Barranco I, Blomberg N, et al. Europe\u2013Africa Collaboration: Working Together to Strengthen Health Research, Implementation, and Equitable Systems. Lancet Glob. Health. 2025;13:e1338\u2013e1340.","journal-title":"Lancet Glob. Health"},{"key":"4927_CR62","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/B978-0-12-800869-0.00012-3","volume":"86","author":"Z-G Xia","year":"2014","unstructured":"Xia Z-G, Wang R-B, Wang D-Q, Feng J, Zheng Q, Deng C-S, et al. China\u2013Africa Cooperation Initiatives in Malaria Control and Elimination. Adv Parasitol. 2014;86:319\u201337.","journal-title":"Adv Parasitol"},{"key":"4927_CR63","unstructured":"Tondel, F; Apiko, P; Koyier, M A Partnership in Progress: Africa and the EU Strive for Global Health and Equitable Access. ECPDM Discussion Paper No. 367 2024. https:\/\/ecdpm.org\/work\/partnership-progress-africa-eu-strive-global-health-equitable-access"},{"key":"4927_CR64","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hcs2.117","volume":"3","author":"AA Abdulwahab","year":"2024","unstructured":"Abdulwahab AA, Okafor UG, Adesuyi DS, Miranda AV, Yusuf RO, Eliseo Lucero\u2010Prisno D III. The African Medicines Agency and Medicines Regulation: Progress, Challenges, and Recommendations. Health Care Science. 2024;3:350\u20139.","journal-title":"Health Care Science"},{"key":"4927_CR65","unstructured":"Plan, B PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA. https:\/\/www.nepad.org\/publication\/pharmaceutical-manufacturing-plan-africa"},{"key":"4927_CR66","doi-asserted-by":"publisher","first-page":"e772","DOI":"10.1016\/S2214-109X(17)30245-0","volume":"5","author":"MG Head","year":"2017","unstructured":"Head MG, Goss S, Gelister Y, Alegana V, Brown RJ, Clarke SC, et al. Global Funding Trends for Malaria Research in Sub-Saharan Africa: A Systematic Analysis. Lancet Glob. Health. 2017;5:e772\u2013e781.","journal-title":"Lancet Glob. Health"},{"key":"4927_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-04972-5","volume":"23","author":"F Amimo","year":"2024","unstructured":"Amimo F. Leveraging Malaria Vaccines and MRNA Technology to Tackle the Global Inequity in Pharmaceutical Research and Production towards Disease Elimination. Malar J. 2024;23:136.","journal-title":"Malar J"},{"key":"4927_CR68","doi-asserted-by":"publisher","first-page":"e1004515","DOI":"10.1371\/journal.pmed.1004515","volume":"22","author":"L Seidlein","year":"2025","unstructured":"Seidlein L. von Roll out and Prospects of the Malaria Vaccine R21\/Matrix-M. PLoS Med. 2025;22:e1004515.","journal-title":"PLoS Med"},{"key":"4927_CR69","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/S1473-3099(24)00752-7","volume":"25","author":"HM Natama","year":"2025","unstructured":"Natama HM, Salkeld J, Som\u00e9 A, Soremekun S, Diallo S, Traor\u00e9 O, et al. Safety and Efficacy of the Blood-Stage Malaria Vaccine RH5.1\/Matrix-M in Burkina Faso: Interim Results of a Double-Blind, Randomised, Controlled, Phase 2b Trial in Children. Lancet Infect Dis. 2025;25:495\u2013506. https:\/\/doi.org\/10.1016\/S1473-3099(24)00752-7","journal-title":"Lancet Infect Dis"}],"container-title":["Discover Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11671-026-04927-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11671-026-04927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:48:13Z","timestamp":1789980493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11671-026-04927-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4927"],"URL":"https:\/\/doi.org\/10.1186\/s11671-026-04927-6","relation":{},"ISSN":["2731-9229"],"issn-type":[{"value":"2731-9229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Consent for publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"459"}}